1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cellectis S.A.

Cellectis S.A.

CMVLF
Cellectis S.A.US flagOther OTC
3.47
USD
+0.39
- -
251.93MMarket Cap
Cellectis S.A.
CMVLF
(Other OTC)

Recent

price

3.47

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
1.47
0.75
0.36
1.01
1.64
1.27
0.71
0.31
0.36
1.2
0.71
0.42
0.01
0.46
0.73
0.68
Revenue per Share
- -
-2.19
-1.45
-3.7
- -
-0.67
-1.91
-2.78
-1.93
-2.41
-1.91
-2.69
-2.33
-1.77
-0.41
-0.67
-0.67
Basic EPS, GAAP
- -
-1.23
-1.36
-1.3
1.93
-0.02
-1.32
-1.54
-1.79
-1.93
-2.93
-2.9
-1.97
-0.45
0.21
-0.43
-0.41
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
5.19
-1.46
-3.63
-6.11
-4.99
-7.73
-9.83
-9.87
-11.92
-13.75
-16.38
-9.58
-7.04
-3.57
-3.27
-3.45
Book Value per Share
- -
-0.61
1.38
-0.14
2.73
8.41
7.75
7.92
11.01
8.35
7.23
5.53
2.75
1.47
1.43
0.75
0.59
Tangible Book Value per Share
- -
14
20
21
26
34
35
36
41
42
43
42
46
57
91
100
100
Basic Weighted Avg Shares
21
21
15
7
26
56
45
25
13
15
51
30
19
1
42
73
68
Sales/Revenue/Turnover
-73.82
-122.1
-175.13
-494.74
-24.25
-55.46
-150.2
-367.83
-825.47
-813.38
-82.87
-341.01
-467.72
-12,887.81
-143.48
-45.34
-64.73
Operating Margin (%)
2
- -
5
3
2
2
2
3
2
7
8
14
18
19
20
20
20
Depreciation Expense
-11
-31
-29
-77
- -
-23
-67
-99
-79
-102
-81
-114
-106
-101
-37
-68
-67
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-52.98
-149.06
-193.75
-1,033.23
0.09
-40.81
-150.1
-394.51
-618.12
-672.09
-158.79
-376.32
-553.64
-13,385.3
-88.57
-92.66
-98.76
Profit Margin (%)
31
44
25
-4
69
281
256
278
441
329
263
176
81
78
121
90
70
Working Capital
2
68
4
5
3
- -
- -
- -
1
47
100
90
63
71
78
79
78
LT Debt
50
37
71
3
72
288
275
284
450
355
309
236
126
85
131
76
60
Total Equity
- -
- -
- -
- -
-14.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
-1.26
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-33.07
Return on Capital (%)
- -
-50.18
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
14
12
9
LT Borrowings
50
51
52
LT Finance Leases
29
28
26
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
101
Market Capitalization
261
441
309

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
221
236
205
Cash, Cash Equivalents & STI
190
209
186
Accounts Receivable, Net
8
14
5
Inventories
- -
- -
- -
Total Current Liabilities
149
146
134
Payables & Accruals
25
28
24
ST Debt
14
12
9
Deferred Revenue
94
97
93

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.72%
-18.06%
-42.07%
Free Cash Flow
510.33%
-119.59%
-324.25%
Net Income, GAAP
28.04%
9.85%
83.87%
Sales/Revenue/Turnover
544.22%
1,059.96%
75.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
8
16
13
42
2025
11
17
35
10
73
2026
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
-0.28
-0.23
- -
-0.41
2025
-0.18
- -
0.01
-0.26
-0.67
2026
-0.18
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Nexera Technologies Ltd (NEXR)
Kidswell Bio Corporation (4584.T)
NeuBase Therapeutics, Inc. (NBSE)
Corcept Therapeutics Incorporated (0I3Q.L)
Foghorn Therapeutics Inc. (FHTX)
NGM Biopharmaceuticals, Inc. (NGM)
Business
Cellectis SA is a clinical-stage biopharmaceutical company focused on developing gene-edited allogeneic CAR T-cell therapies for cancer treatment using its proprietary TALEN gene-editing platform. The company engineers off-the-shelf UCART product candidates from healthy donor T-cells, including fully owned lasme-cel (UCART22) targeting CD22 for B-cell acute lymphoblastic leukemia in Phase 1/2 trials with Phase 2 enrollment expected in Q4 2025; eti-cel (UCART20x22) dually targeting CD20/CD22 for non-Hodgkin lymphoma in Phase 1 with readout anticipated late 2025; and licensed programs such as cema-cel (ALLO-501A) targeting CD19 for large B-cell lymphoma in pivotal Phase 2 by partner Allogene; ALLO-316 targeting CD70 for renal cell carcinoma; and IOV-4001 for melanoma and non-small cell lung cancer by Iovance. Founded in 1999 and headquartered in Paris, France, with manufacturing facilities in Paris and Raleigh, North Carolina, Cellectis operates globally through strategic partnerships with Allogene, Servier, Iovance, Primera and AstraZeneca. Recent developments include a $140 million equity investment from AstraZeneca in 2024 providing up to 44% ownership potential and advancing their joint research collaboration agreement initiated in 2023, under which Cellectis received $47 million by year-end 2024 comprising upfront payments, milestones and reimbursements for developing up to 10 novel cell and gene therapies in oncology, immunology and rare diseases; completion of a 40 million euro credit facility with the European Investment Bank in December 2024; and positive end-of-Phase 1 FDA interactions in July 2025 for lasme-cel and eti-cel, bolstering its cash position of $264 million as of December 31, 2024, to fund operations into mid-2027.